title: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
abstract: The aim of this study was to test the hypothesis that use of tiotropium, a new long-acting anticholinergic bronchodilator, would be associated with sustained reduction in lung hyperinflation and, thereby, would improve exertional dyspnoea and exercise performance in patients with chronic obstructive pulmonary disease. A randomised, double-blind, placebo-controlled, parallel-group study was conducted in 187 patients (forced expiratory volume in one second 44 +/- 13% pred): 96 patients received 18 microg tiotropium and 91 patients received placebo once daily for 42 days. Spirometry, plethysmographic lung volumes, cycle exercise endurance and exertional dyspnoea intensity at 75% of each patient's maximal work capacity were compared. On day 42, the use of tiotropium was associated with the following effects at pre-dose and post-dose measurements as compared to placebo: vital capacity and inspiratory capacity (IC) increased, with inverse decreases in residual volume and functional residual capacity. Tiotropium increased post-dose exercise endurance time by 105 +/- 40 s (21%) as compared to placebo on day 42. At a standardised time near end-exercise (isotime), IC, tidal volume and minute ventilation all increased, whilst dyspnoea decreased by 0.9 +/- 0.3 Borg scale units. In conclusion, the use of tiotropium was associated with sustained reductions of lung hyperinflation at rest and during exercise. Resultant increases in inspiratory capacity permitted greater expansion of tidal volume and contributed to improvements in both exertional dyspnoea and exercise endurance.
authors.affiliation: Respiratory Investigation Unit, Dept of Medicine, Queen's University, Kingston, Ontario, Canada. odonnell@post.queensu.ca
authors.forename: D E
authors.initials: DE
authors.lastname: O'Donnell
authors.forename: T
authors.initials: T
authors.lastname: Flüge
authors.forename: F
authors.initials: F
authors.lastname: Gerken
authors.forename: A
authors.initials: A
authors.lastname: Hamilton
authors.forename: K
authors.initials: K
authors.lastname: Webb
authors.forename: B
authors.initials: B
authors.lastname: Aguilaniu
authors.forename: B
authors.initials: B
authors.lastname: Make
authors.forename: H
authors.initials: H
authors.lastname: Magnussen
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004417:Dyspnea / Q000188:drug therapy* / Q000503:physiopathology; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D010807:Physical Endurance; D010991:Plethysmography; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology*; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D013147:Spirometry; D000069447:Tiotropium Bromide
chemical_list: D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide